Taken together, these results revealed a signaling pathway from skeletal muscles to the liver via the IRF4-FSTL1-DIP2A/CD14 pathway in the pathogenesis of NASH. The gene discussed is DIP2A; the disease is metabolic dysfunction-associated steatohepatitis.